Comparative Effectiveness of Clopidogrel Versus Aspirin for Primary Prevention in High-Risk Patients with Type 2
Soo Hyun Kang1,2, Joonpyo Lee3, Jung Ho Kim1,4,5
1Gachon Medical Research Institute, Gachon Biomedical Convergence Institute, Gachon University Gil Medical Center, Incheon 21565, Republic of Korea.
Insights
For high-risk diabetes patients without prior cardiovascular disease, clopidogrel showed similar effectiveness to aspirin but a trend towards reduced gastrointestinal bleeding, especially in males.
Area of Science:
- Cardiology
- Pharmacology
- Preventive Medicine
Background:
- Aspirin is recommended for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in high-risk diabetes patients, but bleeding risks, particularly gastrointestinal (GI) bleeding, complicate its use.
- Alternative antiplatelet strategies are needed due to inconsistent evidence supporting aspirin's benefits versus its risks.
Purpose of the Study:
- To compare the efficacy and bleeding risk of clopidogrel versus aspirin for primary prevention in high- and very high-risk diabetes patients without a history of ASCVD.
- To evaluate clopidogrel as a potentially safer alternative to aspirin, focusing on GI bleeding events.
Main Methods:
- A propensity score-matched analysis of 902 pairs of patients from the Korean National Health Insurance Service data.
- Primary endpoint: net adverse clinical events (NACEs) including death, myocardial infarction (MI), stroke, intracranial hemorrhage (ICH), and GI bleeding.
- Secondary endpoints: efficacy (death, MI, stroke) and bleeding outcomes (GI bleeding, ICH).
Main Results:
- Clopidogrel demonstrated no significant difference compared to aspirin in NACE incidence (HR: 0.97) or efficacy endpoints (HR: 1.02).
- A trend towards significantly lower GI bleeding was observed with clopidogrel (HR: 0.48), though not statistically significant.
- In subgroup analysis, male patients receiving clopidogrel showed a significantly lower NACE risk (HR: 0.73) than those on aspirin.
Conclusions:
- Clopidogrel may be a suitable alternative to aspirin for primary prevention in high-risk male diabetes patients, especially those with increased GI bleeding risk.
- These findings support personalized antiplatelet therapy choices based on individual patient risk profiles.
Abstract:
Background and Objectives: The benefits of aspirin for primary prevention of atherosclerotic cardiovascular disease (ASCVD) among high-risk patients with diabetes are controversial owing to bleeding risk. Current guidelines recommend the use of aspirin in high-risk patients with diabetes; however, the supporting evidence is inconsistent, primarily due to an increased risk of gastrointestinal (GI) bleeding. Given these concerns, it is important to explore alternative antiplatelet strategies. Clopidogrel, a widely used P2Y12 inhibitor, has been suggested to cause fewer GI bleeding events than aspirin. Accordingly, we aimed to compare the efficacy and bleeding risk of clopidogrel versus aspirin in high- and very high-risk populations with diabetes without prior ASCVD using the Korean National Health Insurance Service data. Materials and Methods: Propensity score-matching was performed to reduce baseline imbalances. The primary endpoint was net adverse clinical events (NACEs), defined as a composite of all-cause death, myocardial infarction (MI), stroke, intracranial hemorrhage (ICH), and gastrointestinal GI bleeding. Secondary endpoints included efficacy (composite of all-cause death, MI, and stroke) and bleeding outcomes (GI bleeding and ICH). Results: Among 10,453 patients (9550 on aspirin and 903 on clopidogrel), 902 matched pairs were analyzed. Clopidogrel showed no significant difference compared with aspirin in NACE incidence (hazard ratio [HR]: 0.97; 95% confidence interval [CI]: 0.79-1.19), efficacy endpoints (HR: 1.02; 95% CI: 0.82-1.26), or individual outcomes (MI, stroke, all-cause death). Clopidogrel demonstrated a trend towards lower GI bleeding (HR: 0.48; 95% CI: 0.23-1.01), although not significant. In subgroup analysis, male patients on clopidogrel had significantly lower NACE risk than those on aspirin (HR: 0.73; 95% CI: 0.54-0.99). Conclusions: These findings suggest that clopidogrel may be considered a preferable alternative to aspirin for primary prevention in high-risk male patients with diabetes, particularly those with an elevated risk for gastrointestinal bleeding, guiding personalized antiplatelet therapy choices in clinical practice.
More Related Videos
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Diabetes Mellitus: Type 2 and Gestational
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
01:23Dipeptidyl Peptidase 4 Inhibitors
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:27Coronary Artery Disease V: Interprofessional Care